1. A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma 
Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 1, Pages e6 (January 2018)
DOI: /j.clml
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Diagram
Clinical Lymphoma, Myeloma and Leukemia  , e6DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Risk of Bias Summary. ∗Assessment of Blinding of Participants and Personnel Was Not Applicable Because All Trials Were Open Label. The Trials Were Listed as Having an Unclear Risk of Bias Owing to the Restrictions of Choice Within the Bias Tool. Green Indicates a Low Risk of Bias; Yellow, an Unclear Risk of Bias; and Red, a High Risk of Bias
Clinical Lymphoma, Myeloma and Leukemia  , e6DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

4. Figure 3 Grade ≥ 3 Hematologic Toxicities
Abbreviations: B-R = bendamustine, rituximab; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisolone; FCM = fludarabine, cyclophosphamide, mitoxantrone; F-R = fludarabine, rituximab; G3+ = grade ≥ 3; HD = high dose; Ibrut = ibrutinib; IC = investigator's choice; Lenalid = lenalidomide; maint, maintenance; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-FCM = rituximab, fludarabine, cyclophosphamide, mitoxantrone; ritux = rituximab; Tems = temsirolimus.
Clinical Lymphoma, Myeloma and Leukemia  , e6DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions